

# Dr Andrew J Gleason

## Psychiatrist

MB BS (HONS), BSc, Cert Old Age Psych, FRANZCP, AFRACMA



### Academic and Professional Qualifications

Member, Faculty of Consultation-Liaison Psychiatry Royal Australian and New Zealand College of Psychiatrists	2015-
Associate Fellow, Royal Australasian College of Medical Administrators	2014-
Member, Faculty of Psychiatry of Old Age Royal Australian and New Zealand College of Psychiatrists	2014-
Certificate in Psychiatry of Old Age Royal Australian and New Zealand College of Psychiatrists	2014
Fellowship Royal Australian and New Zealand College of Psychiatrists	2012
Bachelor of Medicine and Bachelor of Surgery with Honours The University of Sydney	2005
Bachelor of Science in Biology (Molecular Genetics) The University of Sydney	2001

### Current Appointment

Senior Staff Specialist in Consultation-Liaison Psychiatry Concord Hospital, Sydney	2020-
Clinical Lead Department of Consultation-Liaison Psychiatry Concord Hospital, Sydney	2020-
Consultant Old Age and Neuropsychiatry Northern Tasmania Huntington's Disease Service and Older Person's Mental Health Service, Launceston (funded by Rural Outreach Fund)	2014-
Honorary Principal Research Fellow Melbourne Dementia Research Centre Florey Institute of Neuroscience and Mental Health University of Melbourne	2018-

### Previous Positions

Head, Aged Psychiatry Research Alfred Health, Melbourne	2016-2020
Consultant Old Age Psychiatrist Cognitive Decline and Memory Service Alfred Health, Melbourne	2015-2020
Consultant Neuropsychiatrist Comprehensive Epilepsy Service and Movement Disorders Service Alfred Health, Melbourne	2017-2020



Visiting Medical Officer in Aged Psychiatry Clinical Trials Research Alfred Health, Melbourne	2015-2020
Senior Specialist in Neuropsychiatry State-wide Progressive Neurological Diseases Service Calvary Healthcare, Bethlehem, Melbourne	2016-2020
Consultation-Liaison Neuropsychiatrist and Old Age Psychiatrist Cabrini Hospital, Melbourne	2017-2020
Consultation-Liaison Neuropsychiatrist and Old Age Psychiatrist John Fawkner and Brunswick Private Hospitals	2013-2016
Consultant Old Age Psychiatrist in private practice Albert Road Clinic, Melbourne	2013-2016
Honorary Fellow Department of Psychiatry The University of Melbourne	2014-2017
Consultant Old Age Psychiatrist Melbourne Health	2012-2014
Senior Neuropsychiatry Registrar Neuropsychiatry Unit, The Royal Melbourne Hospital	2011-2012
Senior Psychiatry Registrar St Vincent's Health, Melbourne	2009-2011
Psychiatry Registrar Sydney South West Area Health Service	2007-2009
Hospital Medical Officer The Alfred Hospital, Melbourne	2006-2007
Intern Nepean Hospital, Sydney	2005-2006
<b>Awards</b>	
RANZCP Foundation Early Career Research Grant	2020
RANZCP Faculty of Psychiatry of Old Age Psychiatric Trainee Prize for Scholarly Project	2015
Membership of the Melbourne Medical School Academy of Teachers (awarded for contributions to medical student teaching), the University of Melbourne	2013
Harry J Clayton Memorial Prize for Medicine and Clinical Medicine, the University of Sydney	2004
Australian Medical Association J.G. Hunter Research Fellowship	2003
Royal College of Pathologists of Australasia Scholarship in Pathology for Medical Schools	2002
John Flood Memorial Scholarship, the University of Sydney Faculty of Medicine	2002



## Current Clinical Trials Experience

### Co-investigator

The Australian Dementia Network (ADNeT). Screening for trials and longitude research on trials ready cohort (TRC). Macquarie University. 2021-present

The Australian multi domain Approach to Reduce dementia risk by protecting brain health with Lifestyle intervention study; a 2-year, single-blind, multi-site, randomised study (AU-ARROW). Macquarie University. 2021-present

## Previous Clinical Trials Experience

### Principal investigator

An Open-label Long-term Extension Safety Study of Intranasal Esketamine in Treatment-resistant Depression (Janssen SUSTAIN-3; TRD3008)

A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study to Evaluate the Efficacy and Safety of E2609 in Subjects with Early Alzheimer's Disease (Eisai Mission AD, E2609-G000-301)

A Phase 2 Study of BIIB092 in Participants with Early Alzheimer's Disease (Biogen TANGO; 251AD201)

An Extension Study of ANAVEX2-73 in Patients with Mild to Moderate Alzheimer's Disease (Anavex 2-73-003)

A Multinational, Multi-centre, Randomized, Double-blind, Active comparator, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Donepezil Transdermal Patch in Patients with Alzheimer's Disease (iCure IPI-003)

An Open-label, Long-term Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression (Janssen SUSTAIN-2; ESKETINTRD3004)

A Multicentre, Open-Label, Long-Term Extension of Phase III Studies (BN29552/BN29553) of Crenezumab in Patients with Alzheimer's Disease (Roche CREAD, BN29552)

A Phase III, Multicentre, Randomized, Double-Blind Placebo-Controlled, Parallel-Group, Efficacy and Safety Study of Crenezumab in Patients with Prodromal to Mild Alzheimer's Disease (Roche CREAD, BN29552)

Randomized, Double-Blind, Placebo Controlled, Multi-Center Registration Trial to Evaluate the Efficacy and Safety of TTP488 in Patients with Mild Alzheimer's disease Receiving Acetylcholinesterase Inhibitors and/or memantine (VTV Steadfast; TTP488-301)

Open Label Extension Study for Continued Safety and Efficacy Evaluation of Azeliragon in Patients with Mild Alzheimer's Disease (VTV Steadfast; TTP488-303)

A Phase 3, double-blind, randomised study of RVT-101 versus placebo when added to existing stable donepezil treatment in subjects with mild to moderate Alzheimer's disease (Axovant Mindset, RVT-101-3001)

Effect of Passive Immunization on the Progression of Mild Alzheimer's Disease: Solanezumab (LY2062430) Versus Placebo (Eli Lilly LZAX, H8A-MC-LZAX(c))



## Sub-investigator

Randomised, double-blind, parallel-group, placebo-controlled study of Lu AE58054 in patients with mild-moderate Alzheimer's disease treated with an acetylcholinesterase inhibitor; Study 3 (Lundbeck Starbright; 14863A)

A Phase IIa Study of ANAVEX2-73 Adaptive-Trial-Design with Repeated Doses, Maximum Tolerated Dose Finding, Pharmacodynamic Investigation and Bioavailability Evaluation in Patients with Mild to Moderate Alzheimer's Disease with a 52 Week Open Label Follow-Up Period (Anavex 2-72-002; Anavex 2-73)

A 26-Week Extension Study of the Safety and Clinical Effects of EVP-6124 in Subjects with Alzheimer's Disease Currently or Previously Receiving an Acetylcholinesterase Inhibitor Medication (EnVivo EVP-6124-026; EVP-6124)

A Randomized, Multicentre, Double-Blind, Placebo-Controlled, Phase III Clinical Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Patients with Manifest Huntington's Disease (F.Hoffman-La Roche Ltd, BN40423)

A Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Single and Multiple Doses of AL002 in Healthy Participants and in Participants with Mild to Moderate Alzheimer's Disease. (Alector AL002-1).

A Phase 2b/3, Double-Blind, Randomized, Placebo-Controlled 48-week Safety and Efficacy trial of ANAVEX2-73 for the Treatment of Early Alzheimer's Disease (Anavex2-73-004)

A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy, and Safety Study of MTAU9937A (RO7105705) in Patients with Prodromal to Mild Alzheimer' Disease (Genentech GN39763; Tauriel)

Deferiprone to Delay Dementia (The 3D Study): a clinical proof of concept study (DEF001)

A Study to Evaluate the Safety and Efficacy of CT1812 in Subjects with Mild to Moderate Alzheimer's Disease (Cognition Therapeutics; COG0201).

A Multicentre, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-120101 Administered Intrathecally in Patients with Huntington's Disease (WAVE Life Sciences, WVE-HDSNP1-001)

A Multicentre, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-120102 Administered Intrathecally in Patients with Huntington's Disease (WAVE Life Sciences, WVE-HDSNP2-001)

Enrol-HD: A Prospective Registry Study in a Global Huntington's Disease Cohort

A randomised controlled trial of theta burst stimulation for treatment of cognitive impairment in mild to moderate Alzheimer's disease. Hoy K, Fitzgerald P, Gleason A. (Investigator-initiated project) Funded by: Mason Foundation National Medical Program, 2018, AU\$100,000



## Publications

### Books

Castle D, Bassett, King J, Gleason A. *A Primer in Clinical Psychiatry*. 2nd ed. Chatswood: Churchill Livingstone; 2013

### Peer-reviewed journal articles

Gleason A, Bush AI. Iron and ferroptosis as therapeutic targets in Alzheimer's disease. *Neurotherapeutics*. 2020, in press.

Gleason A, Ayton S, Bush AI. Unblinded by the light: ARIA in Alzheimer's clinical trials. *European Journal of Neurology*. 2020; doi: 10.1111/ene.14484. Epub ahead of print.

Gleason A, Lewis M, Lee SM, Macfarlane S. A preliminary investigation of domestic squalor in people with a history of alcohol misuse: neuropsychological profile and hoarding behaviour – an opportunistic observational study. *International Psychogeriatrics*. 2015; 27(11): 1913-1918.

King J, Hill K, Gleason A. All the world's a stage: evaluating psychiatry role-play-based learning for medical students. *Australasian Psychiatry*. 2015; 23(1): 76-79.

Gleason A, Hayhow B, Walterfang M, Evans A, Mocellin R, Gates P, Velakoulis D. Neuropsychiatric symptoms as the presenting feature of acquired hepatocerebral degeneration. *Australian and New Zealand Journal of Psychiatry*. 2014;48(10): 959-960.

Gleason A, Hayhow B, Emmanuel J, Gaillard F. Cerebral amyloid angiopathy presenting with neuropsychiatric symptoms. *Australian and New Zealand Journal of Psychiatry*. 2014; 48(8): 779-80.

Velakoulis D, Gleason A, Hayhow B, McNeil P, Gaillard F. Frontal meningioma mimicking relapse of schizophrenia. *Australian and New Zealand Journal of Psychiatry*. 2014; 48(5): 486-487.

Hassan I, Shing C, Bajraszewski C, Gleason A, Hayhow B, Velakoulis D. Osmotic demyelination syndrome: an under recognised cause of delirium? *Australian and New Zealand Journal of Psychiatry*. 2013; 21(1): 76-9.

Sketcher B, London, J, Gleason, A. Evidence-based medicine: a position statement is needed. *Australasian Psychiatry*. 2013; 21(1): 76-77.

Gleason A, Castle D. Adult Attention-Deficit Hyperactivity Disorder and Bipolar Disorder. *Advances in Psychiatric Treatment*. 2012; 18(3): 198-204. (Awarded Editor's Pick for the May 2012 issue)

Gleason A, Castle D, Piterman L, Jones K. Bipolar Disorder. *Check Independent Learning Program for GPs*. Unit 468, March 2011.

Turnbull F, Neal B, Ninomiya T, Algert C, Arima H, Barzi F, Bulpitt C, Chalmers J, Fagard R, Gleason A, Heritier S, Li N, Perkovic V, Woodward M, MacMahon S. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. *British Medical Journal* 2008;336(7653):1121-3

Graham IS, Gleason AJ, Keogh GW, Paltridge D, Rogers IR, Walton M, De Paola C, Singh J and McGrath BP. Australian Curriculum Framework for Junior Doctors. *Medical Journal of Australia* 2007; 186 (7): S14-S19.

Gleason AJ, Daly JO, Blackham RE. Prevocational Medical Training and the Australian Curriculum Framework for Junior Doctors: A Junior



Doctor Perspective. **Medical Journal of Australia** 2007; 186 (3):  
114-116



DR ANDREW GLEASON  
[www.MEDirect.com.au](http://www.MEDirect.com.au) P 1300 001 633